SHANGHAI – Bayer AG’s recent purchase of traditional Chinese medicine (TCM) maker Dihon Pharmaceutical Group Co. was viewed by some as a step closer to the legitimization of the TCM drug market, one that occupies about a third to a half of all revenues here.